7 July 2022
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Notice of Results and Investor Presentation
RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the patented long-term implantable biostable polymer, Elast-EonTM, announces the Group will release its audited annual results for the year ended 31 March 2022 on 11 July 2022.
The Group will also conduct an investor presentation which will follow the publication of the Group's final results. The event will take place at 2.00pm on Monday 18 July with Bill Brown (Chairman) and Caroline Stretton (Group Managing Director) presenting from the Company.
The online presentation is open to all existing and potential shareholders. Questions can be submitted during the presentation to be addressed at the end.
To register for the event, please visit www.equitydevelopment.co.uk/news-and-events/rua-life-sciences-fyresults-18july2022.
A recording of the presentation will be available shortly afterwards on the Equity Developments website.
For further information contact:
RUA Life Sciences plc
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
Caroline Stretton, Group Managing Director Tel: +44 (0) 7789 901269
Cenkos Securities plc (Nominated Adviser and Broker) Tel: +44 (0) 20 7397 8900
Giles Balleny/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-EonTM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and over 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
| RUA Medical: | End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist. |
| RUA Biomaterials: | Licensor of Elast-EonTM polymers to the medical device industry. |
| RUA Vascular: | Commercialisation of open surgical vascular grafts and patches
|
| RUA Structural Heart: | Development of polymeric leaflet systems for heart valves. |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.